These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 18794453)

  • 21. [Hematologic malignancies/ pediatric malignancies-chronic myeloid leukemia].
    Usui N
    Gan To Kagaku Ryoho; 2011 May; 38(5):744. PubMed ID: 21717663
    [No Abstract]   [Full Text] [Related]  

  • 22. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
    Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
    Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CT and MRI findings in sclerodermatous chronic graft vs. host disease.
    Dumford K; Anderson JC
    Clin Imaging; 2001; 25(2):138-40. PubMed ID: 11483427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial effect of intravenous lidocaine in cutaneous chronic graft-versus-host disease secondary to donor lymphocyte infusion.
    Voltarelli JC; Ahmed H; Paton EJ; Stracieri AB; Holman P; Bashey A; Coutinho M; Simoes BP; Ball ED; Carrier E
    Bone Marrow Transplant; 2001 Jul; 28(1):97-9. PubMed ID: 11498752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus.
    Eckardt A; Starke O; Stadler M; Reuter C; Hertenstein B
    Oral Oncol; 2004 Sep; 40(8):811-4. PubMed ID: 15288836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.
    Molés-Poveda P; Montesinos P; Sanz-Caballer J; de Unamuno B; Piñana JL; Sahuquillo A; Botella-Estrada R
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):241-247. PubMed ID: 29254596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic hematopoietic stem cell transplantation for the treatment of chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Xu LP; Huang XJ
    Chin Med J (Engl); 2013 Feb; 126(4):768-74. PubMed ID: 23422204
    [No Abstract]   [Full Text] [Related]  

  • 28. October 2015 Snapshot Dx Quiz: Linking Science to Patient Care.
    Nusbaum AG; Miteva M
    J Invest Dermatol; 2015 Oct; 135(10):e33. PubMed ID: 26358389
    [No Abstract]   [Full Text] [Related]  

  • 29. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?
    Ruiz-Argüelles GJ; Tarin-Arzaga LC; Gonzalez-Carrillo ML; Gutierrez-Riveroll KI; Rangel-Malo R; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Gómez-Almaguer D; Giralt S
    Bone Marrow Transplant; 2008 Jul; 42(1):23-8. PubMed ID: 18612313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.
    Breccia M; Alimena G
    Leuk Res; 2009 Jul; 33(7):871-5. PubMed ID: 19307018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imatinib treatment of generalized localized scleroderma (morphea).
    Moinzadeh P; Krieg T; Hunzelmann N
    J Am Acad Dermatol; 2010 Nov; 63(5):e102-4. PubMed ID: 20950732
    [No Abstract]   [Full Text] [Related]  

  • 32. Successful long-term use of imatinib mesylate in pediatric patients with sclerodermatous chronic GVHD.
    Kim H; Kim NH; Kang HJ; Lee JW; Kim MS; Park KD; Shin HY; Ahn HS
    Pediatr Transplant; 2012 Dec; 16(8):910-2. PubMed ID: 23050745
    [No Abstract]   [Full Text] [Related]  

  • 33. Complete vaginal obstruction with hematometra after hematopoietic stem cell transplantation for chronic myeloid leukemia: a case report.
    Rodolakis A; Thomakos N; Harhalakis N; Iconomou T; Antsaklis A
    J Reprod Med; 2007 Oct; 52(10):959-61. PubMed ID: 17977175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does early stem-cell transplantation have a role in chronic myeloid leukaemia? Against the proposal.
    Rosti G; Baccarani M
    Lancet Oncol; 2005 Sep; 6(9):722-3. PubMed ID: 16161267
    [No Abstract]   [Full Text] [Related]  

  • 35. A case of sclerodermatous graft-versus-host disease following autologous peripheral blood stem cell transplantation.
    Nakamura K; Kawakami Y; Oyama N; Kaneko F; Abe H; Sagara H; Ohto H
    J Dermatol; 2006 Feb; 33(2):135-8. PubMed ID: 16556284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update: chronic myelogenous leukemia clinical practice guidelines.
    O'Brien SM; Kantarjian H; Radich J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S29-40. PubMed ID: 19795574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion.
    Skert C; Patriarca F; Zaja F; Tomadini V; Fanin R
    Bone Marrow Transplant; 2005 Mar; 35(5):523-4. PubMed ID: 15654352
    [No Abstract]   [Full Text] [Related]  

  • 38. Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment.
    Dazzi F; Fozza C
    Best Pract Res Clin Haematol; 2007 Jun; 20(2):311-27. PubMed ID: 17448964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
    Minami Y; Naoe T
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.